Wave Life Sciences Ltd. Stock

Equities

WVE

SG9999014716

Biotechnology & Medical Research

Market Closed - Nasdaq 01:00:00 2024-07-03 pm EDT 5-day change 1st Jan Change
5.32 USD +1.92% Intraday chart for Wave Life Sciences Ltd. +6.61% +5.35%
Sales 2024 * 74.63M Sales 2025 * 50.99M Capitalization 651M
Net income 2024 * -89M Net income 2025 * -139M EV / Sales 2024 * 6.8 x
Net cash position 2024 * 144M Net cash position 2025 * 113M EV / Sales 2025 * 10.6 x
P/E ratio 2024 *
-7.65 x
P/E ratio 2025 *
-5.59 x
Employees 267
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.47%
More Fundamentals * Assessed data
Dynamic Chart
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 3000 Growth Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell Microcap Growth Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 3000E Growth Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 2000 Growth Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 2500 Growth Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell Small Cap Comp Growth Index CI
WAVE Life Sciences Discloses 'Positive' Phase 1b/2a Data From Huntington's Disease Treatment But Shares Fall on Neurofilament Concern MT
Nvidia Rebound Buoys Nasdaq as US Equity Futures Trade Mostly Higher Pre-Bell MT
WAVE Life Sciences Discloses 'Positive' Data From Phase 1b/2a Trial of WVE-003 to Treat Huntington's Disease; Shares Rise Pre-Bell MT
Transcript : Wave Life Sciences Ltd. - Special Call
Wave Life Sciences Ltd. Announces Positive Results from Phase 1b/2a Select-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to S&P Pharmaceuticals Select Industry Index CI
Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target MT
Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Posts Q1 Revenue $12.5M, vs. Street Est of $23M MT
More news

Latest transcript on Wave Life Sciences Ltd.

1 day+1.92%
1 week+6.61%
Current month+6.61%
1 month-14.19%
3 months-9.06%
6 months+0.38%
Current year+5.35%
More quotes
1 week
4.87
Extreme 4.87
5.35
1 month
4.25
Extreme 4.25
6.49
Current year
3.50
Extreme 3.5
7.67
1 year
3.50
Extreme 3.5
7.67
3 years
1.16
Extreme 1.16
7.67
5 years
1.16
Extreme 1.16
39.98
10 years
1.16
Extreme 1.16
56.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-11-30
Director of Finance/CFO 54 14-06-30
Chief Tech/Sci/R&D Officer 63 14-07-31
Members of the board TitleAgeSince
Chairman 56 16-11-09
Director/Board Member 66 19-09-03
Director/Board Member 52 17-01-31
More insiders
Date Price Change Volume
24-07-03 5.32 +1.92% 265,837
24-07-02 5.22 -0.29% 896,166
24-07-01 5.235 +4.91% 614,280
24-06-28 4.99 0.00% 3,722,437
24-06-27 4.99 +14.06% 2,009,972

Delayed Quote Nasdaq, July 03, 2024 at 01:00 pm EDT

More quotes
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.32 USD
Average target price
13.43 USD
Spread / Average Target
+152.42%
Consensus